Skip to main content

Proposed bulletins

Public comments

The bulletins below are in the process of development by the Division of Financial Regulation (DFR). The division is asking for public review and comment as part of that process. All comments received will be given full consideration and a final report discussing our general response as applied to the bulletin’s final version will be released.

Submit comments

Comments can be submitted in the following ways (Please include the bulletin number or name in the subject line of your comment):

Email:
dfr.bulletin@oregon.gov

Mail:
Department of Consumer and Business Services
Division of Financial Regulation
350 Winter St. NE
P.O. Box 14480
Salem, OR 97309-0405

Proposed bulletins

Click titles for details and documents.
Most current on top.

​ Guidance on policy language used in intentional acts exclusions

Summary:
The purpose of this bulletin is to provide property and casualty insurers with guidance on policy language used to exclude coverage of intentional acts. Exclusionary language that applies to losses beyond what the insured intended encompasses not only intentional acts but could exclude coverage of unintended or negligent acts. This is not how intentional acts exclusions have been interpreted in Oregon.

There has been significant time in between when this bulletin first went out for public comment. Therefore the Division of Financial Regulation requests a second round of public comment for 14 days from all stakeholders. Public comment is due 5 p.m. on June 18, 2021. Please submit public comment to DFR.Bulletin@oregon.gov.

Draft Bulletin: Guidance on policy language used in intentional acts exclusions

Last day for public comment: Friday, June 18, 2021 - 5:00 p.m.


Audience: All manufacturers of prescription drugs sold in Oregon

Purpose:
This bulletin clarifies the definition of “new prescription drug” in OAR 836-200-0505, regarding whether a report is required under OAR 836-200-0520 and ORS 646A.689. The term “original new drug application,” for “specialty drug” reports required under ORS 646A.689, includes both novel drugs and acquired drugs previously approved.

The definition of “new prescription drug” for reporting under the Oregon Drug Price Transparency Act

Public comments requested: Please send public comments to DFR.Bulletin@oregon.gov.

Last day for public comment: Friday, February 26, 2021, 5 p.m.



Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how

×